Get started
Author

Mehmet Emin Büyükbayram

Observed names: Buyukbayram, Mehmet Emin, M. Emin Buyukbayram, M. Emin Büyükbayram, Mehmet Buyukbayram, Mehmet E Buyukbayram, Mehmet E Büyükbayram, Mehmet E. Buyukbayram, Mehmet Emin Buyukbayram
ORCID: 0000-0002-5454-7576
Observed ORCID: 0000-0002-5454-7576
OpenAlex ID: A5088799414
The Importance of the Glucose-To-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Treated with Sorafenib
2021 · Ali Yılmaz, Melih Şimşek, et al. · Future Oncology · 24
The value of pretreatment glucose-to-lymphocyte ratio for predicting survival of metastatic gastric cancer
2023 · Zekeriya Hannarici, Ali Yılmaz, et al. · Future Oncology · 17
A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio
2021 · Zekeriya Hannarici, Ali Yilmaz, et al. · Melanoma Research · 17
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group
2023 · Çağlar Ünal, Abdulmunir Azizy, et al. · The Oncologist · 11
PDF
The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker
2024 · Mehmet Buyukbayram, Zekeriya Hannarici, et al. · Breast Cancer Targets and Therapy · 9
A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio.
2021 · Zekeriya Hannarici, Ali Yilmaz, et al. · PubMed · 9
A novel prognostic biomarker in progression free survival for patients with cervical cancer, glucose to c-reactive protein ratio (GCR)
2024 · Mehmet Emin Buyukbayram, Zekeriya Hannarici, et al. · BMC Cancer · 8
PDF
“Pre-Treatment“ and “Post-Treatment” Systemic Inflammatory Markers: Is There Any Prognostic Role for Metastatic Cervical Cancer on Bevacizumab Containing Treatment?
2025 · Serkan Yaşar, Ahmet Kadıoğlu, et al. · Medicina · 3
PDF
Inflammatory parameters in NSCLC with driver mutation
2024 · Mehmet Emin Buyukbayram, Zekeriya Hannarici, et al. · Lung Cancer Management · 3
Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated Surgically
2023 · Murat Bardakci, Derya Demirtas Esmer, et al. · Oncology · 3
Prognostic Value of Albumin-to-CEA Ratio in Metastatic Colorectal Cancer: A Retrospective Study
2026 · Zekeriya Hannarici, Aykut Turhan, et al. · Biomedicines · 2
PDF
Lipegfilgrastim may cause hyperleukocytosis
2022 · Zekeriya Hannarici, Ali Yılmaz, et al. · Journal of Oncology Pharmacy Practice · 2
Association between standardized uptake value and survival in patients with locally advanced or metastatic squamous cell head and neck cancer
2015 · Zeynep Oruc, M. Emin Buyukbayram, et al. · Journal of Oncological Sciences · 2
PDF
Prognostic Value of the Gustave Roussy Immune Score in Patients with Locally Advanced Gastric Cancer Receiving Neoadjuvant FLOT Chemotherapy: A Retrospective Cohort Study
2026 · Aykut Turhan, Mehmet Emin Büyükbayram, et al. · Diagnostics · 1
Prognostic Value of the PILE Score in Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy
2025 · Aykut Turhan, Mehmet Emin Büyükbayram, et al. · Diagnostics · 1
PDF
Effects of educational status and the living environment on the prognosis of head and neck squamous cell carcinoma
2016 · Zeynep Oruç, M. Emin Büyükbayram, et al. · Journal of Oncological Sciences · 1
PDF
Adjuvant chemotherapy patterns and clinicopathological factors associated with survival in patients aged 70 years and older with resected stage II–III colon cancer: a single-center real-world study
2026 · Zekeriya Hannarici, Aykut Turhan, et al. · Journal of Medicine and Palliative Care
PDF
Prognostic Value of the Objective Prognostic Score and Palliative Prognostic Index for Short-Term Mortality in Terminal Cancer Patients Receiving Best Supportive Care: A Prospective Observational Single-Center Study
2026 · Alperen Akansel Çağlar, Zekeriya Hannarici, et al. · Journal of Clinical Medicine
Distinguishing adrenal metastases from benign lesions in NSCLC: the value of clinical and radiological parameters
2026 · Alperen Akansel Çağlar, Zekeriya Hannarici, et al. · BMC Cancer
Chemotherapy intolerance in metastatic non-small cell lung cancer: the role of nutritional status
2026 · Aykut Turhan, Mehmet Emin Büyükbayram · Anatolian Current Medical Journal
PDF
Parameters That May Predict NAC Effectiveness in Hormone-Positive Breast Cancer According to CPS Score
2026 · Mehmet Buyukbayram, Zekeriya Hannarici, et al. · Cancer Management and Research
PDF
New Parameters That May Predict Tumor Regression and Survival in Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
2025 · Mehmet Emin Büyükbayram, Zekeriya Hannarici, et al. · Düzce Tıp Fakültesi Dergisi
PDF
The Relationship Between Vitamin D and Euthyroid Sick Syndrome in Hospitalized Solid Cancer Patients: A Retrospective Study
2025 · Mehmet Emin Buyukbayram, Zekeriya Hannarici, et al. · Clinical Medicine Insights Oncology
Survival Comparison and Clinical Characteristics of Sunitinib and Pazopanib in the Treatment of Metastatic Renal Cell Cancer, Single Center Real-Life Data
2025 · Mehmet Emin Büyükbayram, Zekeriya Hannarici, et al. · Kafkas Journal of Medical Sciences
PDF
Synchronous Widely Cutaneous Metastasis from Primary Gastric Cancer: A Case Report
2024 · Mehmet Emin Buyukbayram · SciBase Gastroenterology and Hepatology
PDF
Works count: 35
Citation count: 113
H-index: 7
I10-index: 4
Year
Topic
Type